Skip to main content

Table 1 Baseline characteristics

From: Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma

Variables   All PRC2 expression P value
N (%) Low or Intermediate High
Sex Male 62 (59%) 59 (56%) 3 (3%) 0.965
Female 43 (41%) 41 (39%) 2 (2%)  
Age at diagnosis (year, median, range) 26.8 (1–78) 26.3 ± 18.7 35.6 ± 19.7 0.280
Diagnosis Synovial sarcoma 18 (17%) 18 (17%) 0 (0%) 0.400
Rhabdomyosarcoma 28 (27%) 25 (24%) 3 (3%)  
Ewing sarcoma 15 (14%) 14 (13%) 1 (1%)  
Osteosarcoma 30 (29%) 29 (28%) 1 (1%)  
Others 14 (13%) 14 (13%) 0 (0%)  
Primary Site Head/Neck 20 (19%) 20 (19%) 0 (0%) 0.512
Trunk 29 (28%) 27 (26%) 2 (2%)  
Upper Extremity 12 (11%) 12 (11%) 0 (0%)  
Lower Extremity 44 (42%) 41 (39%) 3 (3%)  
Histologic Grade Grade 1 4 (4%) 4 (4%) 0 (0%) 0.853
Grade 2 2 (2%) 2 (2%) 0 (0%)  
Grade 3 99 (95%) 94 (90%) 5 (5%)  
Initial distant metastasis No 83 (83%) 80 (80%) 3 (3%) 0.531
Yes 17 (17%) 16 (16%) 1 (1%)  
Surgery No 6 (6%) 5 (5%) 1 (1%) 0.259
Yes 99 (95%) 95 (91%) 4 (4%)  
Resection margin R0 68 (69%) 66 (67%) 2 (2%) 0.636
R1 29 (29%) 27 (27%) 2 (2%)  
R2 2 (2%) 2 (2%) 0 (0%)  
Stage I or II 53 (50%) 52 (49%) 1 (1%) 0.205
III or IV 52 (50%) 48 (46%) 4 (4%)  
Chemotherapy No 33 (35%) 30 (31%) 3 (4%) 0.081
Yes 63 (65%) 62 (64%) 1 (1%)  
Radiotherapy No 57 (60%) 56 (59%) 1 (1%) 0.144
Yes 38 (40%) 35 (37%) 3 (3%)  
\